Atea Pharmaceuticals Inc (AVIR) Stock Price, Quote & News

Company Profile

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection....

Industry: Biotechnology

Sector: Healthcare

Phone: 857 284 8891

Website: ateapharma.com

Address:

225 Franklin Street, Suite 2100, Boston, United States

laaarsas Apr. 11 at 3:45 PM

$AVIR if ph3 hits what share price will we see?

1 · Reply

laaarsas Apr. 9 at 2:12 PM

$AVIR so what do ppl expect here?

0 · Reply

Merlintrader Apr. 5 at 6:38 AM

$AVIR https://www.merlintrader.com/atea-pharmaceuticals-avir-deep-dive/

1 · Reply

SuperGreenToday Apr. 2 at 5:29 PM

$AVIR Share Price: $5.78 Contract Selected: Oct 16, 2026 $5 Calls Buy Zone: $0.85 – $1.05 Target Zone: $1.60 – $1.95 Potential Upside: 77% ROI Time to Expiration: 196 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

laaarsas Apr. 2 at 9:58 AM

$AVIR Lol I just ran some numbers. Total pts regardless of adherece in ph2 was 259. 222 of them non-cirrhotic, leaves 37 pts cirrhotic. 245/259 pts had SVR12. Means 14 failed. In non-cirr, it was 215/222. Leaves 7 left i cirrhotic. Meaning only 30/37 had SVR in cirrhotic regardless of adherecence. This is AWFULLY bad. And look how the company presents data. Shows non-cirr and all subgroups. Fkn scammers. Pieces of shit. Gfto. This should be criminal. It's fkn misleading ppl who are not as smart as me and can see this. It should be illegal. What they should show is that only 81% has SVR12 in cirrhotics in what is the mITT in C-BEYOND. Will you salvage that with 12wk instead of 8wk? Not likely. Not impossible. But not likely. Stinky.

0 · Reply

laaarsas Apr. 2 at 9:47 AM

$AVIR I change my mind again. No granular data from phase 2 on regardless of adherence. 9 more pts failed in that group compared to PE. Most likely majority was in cirrhosis, otherwise they would have showed that it was not. Cirrhosis still mega risk here. Far away from convinced. Cirrhosis high risk of bad data. 12wk might not salvage. Highrisk play. Stay away or low-sized bet.

0 · Reply

laaarsas Apr. 2 at 9:07 AM

$AVIR Risky play. Cirrhosis data is kinda stinky. Too bad. Stay away or only minor position.

1 · Reply

laaarsas Apr. 2 at 8:48 AM

$AVIR How do you think market will react if study overall is good but there is failure in cirrhotics compated to ctrl?

1 · Reply

laaarsas Apr. 2 at 8:38 AM

$AVIR Wild card is responce among cirrhotics, right?

0 · Reply

laaarsas Apr. 2 at 8:20 AM

$AVIR You think the trials will succeed yes or no?

0 · Reply

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

ACLX

Mar 5, 2026, 4:05 PM EST - 6 weeks ago

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 26, 2026, 7:00 AM EST - 7 weeks ago

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026

Feb 24, 2026, 7:00 AM EST - 2 months ago

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

Jan 8, 2026, 7:00 AM EST - 3 months ago

Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:00 AM EST - 3 months ago

Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 22, 2025, 7:00 AM EST - 4 months ago

Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Nov 19, 2025, 7:00 AM EST - 5 months ago

Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 4:05 PM EST - 5 months ago

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 7, 2025, 8:00 AM EST - 5 months ago

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

Nov 5, 2025, 7:00 AM EST - 5 months ago

Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025

Oct 22, 2025, 7:00 AM EDT - 6 months ago

Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025

Oct 7, 2025, 8:00 AM EDT - 7 months ago

Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

Sep 2, 2025, 7:00 AM EDT - 8 months ago

Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 7, 2025, 4:05 PM EDT - 9 months ago

Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 7:00 AM EDT - 9 months ago

Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025

Jun 24, 2025, 7:00 AM EDT - 10 months ago

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

May 12, 2025, 4:11 PM EDT - 1 year ago

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

May 1, 2025, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

Apr 23, 2025, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025

Apr 17, 2025, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

Apr 9, 2025, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Mar 31, 2025, 7:04 PM EDT - 1 year ago

Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination

Mar 26, 2025, 1:58 PM EDT - 1 year ago

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

Mar 26, 2025, 8:00 AM EDT - 1 year ago

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Mar 21, 2025, 5:54 PM EDT - 1 year ago

Atea Pharmaceuticals Issues Statement Regarding Director Nominations

Mar 19, 2025, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025

Mar 6, 2025, 4:05 PM EST - 1 year ago

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025

Feb 24, 2025, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

Jan 8, 2025, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 5:05 PM EST - 1 year ago

Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process

Dec 16, 2024, 5:00 AM EST - 1 year ago

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

Dec 4, 2024, 3:14 PM EST - 1 year ago

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study

Dec 4, 2024, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

Nov 26, 2024, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference

Nov 15, 2024, 11:00 AM EST - 1 year ago

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Nov 7, 2024, 4:05 PM EST - 1 year ago

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

Aug 28, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024

May 29, 2024, 7:00 AM EDT - 2 years ago

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 22, 2024, 7:00 AM EDT - 2 years ago

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

Apr 29, 2024, 7:00 AM EDT - 2 years ago

Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024

Mar 27, 2024, 7:00 AM EDT - 2 years ago

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Feb 28, 2024, 4:05 PM EST - 2 years ago

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 21, 2024, 7:00 AM EST - 2 years ago

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

Jan 8, 2024, 4:05 PM EST - 2 years ago

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

laaarsas Apr. 11 at 3:45 PM

$AVIR if ph3 hits what share price will we see?

1 · Reply

laaarsas Apr. 9 at 2:12 PM

$AVIR so what do ppl expect here?

0 · Reply

Merlintrader Apr. 5 at 6:38 AM

$AVIR https://www.merlintrader.com/atea-pharmaceuticals-avir-deep-dive/

1 · Reply

SuperGreenToday Apr. 2 at 5:29 PM

0 · Reply

laaarsas Apr. 2 at 9:58 AM

0 · Reply

laaarsas Apr. 2 at 9:47 AM

0 · Reply

laaarsas Apr. 2 at 9:07 AM

$AVIR Risky play. Cirrhosis data is kinda stinky. Too bad. Stay away or only minor position.

1 · Reply

laaarsas Apr. 2 at 8:48 AM

$AVIR How do you think market will react if study overall is good but there is failure in cirrhotics compated to ctrl?

1 · Reply

laaarsas Apr. 2 at 8:38 AM

$AVIR Wild card is responce among cirrhotics, right?

0 · Reply

laaarsas Apr. 2 at 8:20 AM

$AVIR You think the trials will succeed yes or no?

0 · Reply

laaarsas Mar. 29 at 10:25 AM

$AVIR Yo what's up?

0 · Reply

OfficialStocktwitsUser Mar. 23 at 7:00 PM

$AVIR RSI: 66.67, MACD: 0.3850 Vol: 0.61, MA20: 5.52, MA50: 4.62 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

OnlyFibs Mar. 14 at 8:38 PM

$AVIR $AVIR 🧬 +40% this month — here's why Evercore PT raised $6 → $10 on Mar 9 Earnings call flagged 'pivotal 2026' Phase 2: 98% SVR12 cure rate for HCV C-BEYOND Phase 3 fully enrolled TOPLINE DATA DUE MID-2026 ← the event $301.8M cash — fully funded chart: $1.43 base → $6.45 parabolic now cooling — $5.38 is the key support hold $5.38 = bounce thesis intact break $4.14 = thesis off ⚠️ binary risk: data hits = $10+ data misses = gap to cash value high risk. high reward. know your size. #AVIR #Biotech #hovdid

0 · Reply

OnlyFibs Mar. 14 at 8:17 PM

$AVIR up 50% on this call..

0 · Reply

Cutlass Mar. 13 at 7:25 PM

$AVIR Strong week ✍️

0 · Reply

erevnon Mar. 9 at 6:54 PM

Evercore ISI Group maintains Atea Pharmaceuticals $AVIR at Outperform and raises the price target from $6 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Following_the_trend Mar. 9 at 3:22 PM

$AVIR Still moving up......

0 · Reply

VintageVibes Mar. 9 at 5:27 AM

$AVIR HCV Phase 3 (C-BEYOND): Enrollment of over 880 patients in North America is complete. Topline results are expected in mid-2026.

0 · Reply

StockScanners Mar. 7 at 4:04 AM

$AVIR keep watch if this holds above 5.48

0 · Reply

Barkingdogs Mar. 6 at 11:01 PM

$AVIR hep c is the ticket!!!

0 · Reply

Barkingdogs Mar. 6 at 10:59 PM

$AVIR Current Focus: The company is focused on its Phase 3 hepatitis C (HCV) program and has initiated a $25 million stock buyback program, signaling confidence in its independent path

0 · Reply

Market Cap	454.93M
Revenue (ttm)	0.00
Net Income (ttm)	-158.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	397,100
Avg Vol	503,484
Day's Range	N/A - N/A
Shares Out	79.67M
Stochastic %K	20%
Beta	0.16
Analysts	Sell
Price Target	$8.00